Management and survival of patients with cancer of unknown primary discussed by a French national multidisciplinary tumour board: a retrospective analysisResearch in context

Summary: Background: Recent clinical trials have shown that molecularly-guided treatments can improve survival in patients with cancers of unknown primary (CUP). However, the feasibility and clinical benefit of these treatments for CUP in a real-life setting remain uncertain. In France, a national...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Célia Dupain, Nicolas Jacquin, Aurélien Latouche, Zoé Nevière, Pierre Gestraud, Abderaouf Hamza, Kenza Nedara, Vincent Cockenpot, Janick Selves, Yves Allory, Laëtitia Chanas, Maud Milder, Isabelle Soubeyran, Hélène Blons, Anna Patrikidou, Axel de Bernardi, Julien Masliah-Planchon, Odette Mariani, Etienne Rouleau, Fabienne Escande, Sandrine Boyault, Pierre Saintigny, Florence de Fraipont, Pierre Blanc, Jennifer Wong, Camille Tlemsani, Isabelle Guillou, Julie Flavius, Noemie Fuentealba, Maud Kamal, Ivan Bièche, Nicolas Servant, Christophe Le Tourneau, Sarah Watson
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2026-01-01
Saila:	The Lancet Regional Health. Europe
Gaiak:	Cancer of unknown primary Multidisciplinary tumour board Next generation sequencing Personalized medicine Survival
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2666776225003163
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!